Drug Profile
Research programme: AGE Formation Inhibitors - Synvista
Alternative Names: ALT-946Latest Information Update: 07 Apr 2009
Price :
$50
*
At a glance
- Originator Alteon
- Developer Synvista Therapeutics
- Class Acetamides; Antihyperglycaemics; Hydrazines; Small molecules
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic nephropathies